Novo Nordisk halts the production of insulin pens, The Guardian reports

Novo Nordisk has been accused of prioritizing profits over the health of people in developing countries after halting the production of its insulin pens, Kaamil Ahmed of The Guardian reports. People living with type 1 diabetes who are reliant on the insulin produced by Novo Nordisk will instead be given glass vials and syringes, which are more inconvenient and harder to use with the same accuracy. Campaigners claim the move is to allow the scaling-up of production of injectable weight-loss drugs.